{"protocolSection":{"identificationModule":{"nctId":"NCT02080832","orgStudyIdInfo":{"id":"HM15378"},"secondaryIdInfos":[{"id":"2P50DA009262-16A1","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2P50DA009262-16A1"}],"organization":{"fullName":"Virginia Commonwealth University","class":"OTHER"},"briefTitle":"Brain Function and Structure in Cocaine Dependence","officialTitle":"Brain Function and Structure in Cocaine Dependence"},"statusModule":{"statusVerifiedDate":"2017-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-02","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2016-02","type":"ACTUAL"},"completionDateStruct":{"date":"2016-02","type":"ACTUAL"},"studyFirstSubmitDate":"2014-03-04","studyFirstSubmitQcDate":"2014-03-04","studyFirstPostDateStruct":{"date":"2014-03-06","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-06-13","resultsFirstSubmitQcDate":"2017-11-21","resultsFirstPostDateStruct":{"date":"2017-12-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2017-11-21","lastUpdatePostDateStruct":{"date":"2017-12-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Virginia Commonwealth University","class":"OTHER"},"collaborators":[{"name":"The University of Texas Health Science Center, Houston","class":"OTHER"},{"name":"National Institute on Drug Abuse (NIDA)","class":"NIH"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The purpose of this study is to examine the role of brain MRI findings in predicting treatment outcomes among individuals with cocaine dependence.","detailedDescription":"The Specific Aims of this project are:\n\nAim 1: To determine whether pretreatment brain activation on fMRI while performing a Go-Nogo task predicts response to pharmacotherapy in cocaine dependent subjects.\n\nHypothesis related to Aim 1:\n\nPretreatment fMRI BOLD activation in cocaine dependent subjects during impulsive responding on the Go-Nogo task predicts 8-week outcome from medication known to enhance serotonin function (citalopram). The regression coefficient of TES on pretreatment mean BOLD activation on the Go-Nogo task will be significantly greater for the citalopram group than the placebo group.\n\nAim 2: To determine whether pretreatment brain activation on fMRI while performing an attentional bias (cocaine Stroop) task predicts response to pharmacotherapy in cocaine dependent subjects.\n\nHypothesis related to Aim 2:\n\nPretreatment fMRI BOLD activation in cocaine dependent subjects during cocaine related words on the cocaine Stroop task predicts 8-week outcome from medication known to enhance serotonin function (citalopram). The regression coefficient of TES on pretreatment mean BOLD activation from the cocaine Stroop task will be significantly greater for the citalopram group than the placebo group."},"conditionsModule":{"conditions":["Cocaine Dependence"],"keywords":["substance abuse","cocaine","impulsivity","serotonin","MRI"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":54,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Medication (Citalopram 20mg)","type":"EXPERIMENTAL","description":"Citalopram (20mg dose)","interventionNames":["Drug: Citalopram"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Medication (Citalopram 40mg)","type":"EXPERIMENTAL","description":"Citalopram 40mg dose","interventionNames":["Drug: Citalopram"]}],"interventions":[{"type":"DRUG","name":"Citalopram","description":"20 mg or 40 mg daily for 8 weeks","armGroupLabels":["Medication (Citalopram 20mg)","Medication (Citalopram 40mg)"],"otherNames":["Celexa","Citalopram HBr"]},{"type":"DRUG","name":"Placebo","description":"Placebo daily for 8 weeks","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Cocaine Use/Treatment Effectiveness Score (TES)","description":"Number of benzoylecgonine negative urines divided by the total number of urines collected","timeFrame":"8 weeks of treatment"}],"otherOutcomes":[{"measure":"fMRI Brain Activation in Right Inferior Frontal Gyrus","description":"Brain activation on fMRI while participants undergo a Go/Nogo task. Percent of significant cluster in Statistical Parametric Mapping (SPM) for contrast of Hard Nogo minus Easy Nogo correlation with treatment effectiveness score.","timeFrame":"Baseline"},{"measure":"fMRI Brain Activation in Right Precentral Gyrus","description":"Brain activation on fMRI while participants undergo a Go/Nogo task. Percent of significant cluster in Statistical Parametric Mapping (SPM) for contrast of Hard Nogo minus Easy Nogo correlation with treatment effectiveness score.","timeFrame":"Baseline"},{"measure":"fMRI Brain Activation in Right Orlandic Operculum","description":"Brain activation on fMRI while participants undergo a Go/Nogo task. Percent of significant cluster in Statistical Parametric Mapping (SPM) for contrast of Hard Nogo minus Easy Nogo correlation with treatment effectiveness score.","timeFrame":"Baseline"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female subjects age 18 to 50 who meet current DSM-IV criteria for cocaine dependence who are seeking treatment.\n\nExclusion Criteria:\n\n1. Current DSM-IV diagnosis of any psychoactive substance dependence other than cocaine, marijuana, nicotine, or alcohol\n2. Have a DSM-IV axis I psychiatric disorder or neurological disease or disorder requiring ongoing treatment and/or making study participation unsafe\n3. Significant current suicidal or homicidal ideation\n4. Medical conditions contraindicating citalopram pharmacotherapy (liver disease, seizure disorder, bleeding disorder, or prolonged QT interval on EKG)\n5. Taking CNS active concomitant medications\n6. Taking medications known to have significant drug interactions with the study medication\n7. Having conditions of probation or parole requiring reports of drug use to officers of the court\n8. Impending incarceration\n9. Pregnant or breast feeding for female patients\n10. Inability to read, write, or speak English\n11. Having plans to leave the immediate geographical area within 3 months\n12. Unwillingness or not competent to sign a written informed consent form\n13. Individuals who have pacemakers, metal or electromechanical implants or metallic foreign bodies\n14. Patients who are known to be HIV positive will not be included due to possible CNS effects of HIV.\n15. Alcohol withdrawal symptoms or history of significant previous alcohol withdrawal symptoms.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Frederick G Moeller, M.D.","affiliation":"Virginia Commonwealth University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Virginia Commonwealth University","city":"Richmond","state":"Virginia","zip":"23298","country":"United States","geoPoint":{"lat":37.55376,"lon":-77.46026}}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"For some consented participants, the imaging scan (MRI) quality was not sufficient to include those participants in the outcome analysis. These participants are captured by the\"excluded from analysis by MRI\" category. fMRI data was only analyzed from participants who underwent MRI scans at UT Houston which can't be combined with MRI scans at VCU.","groups":[{"id":"FG000","title":"Medication Citalopram (20mg Dose)","description":"Citalopram (20mg dose)\n\nCitalopram: 20 mg daily for 8 weeks"},{"id":"FG001","title":"Placebo","description":"Placebo: Placebo daily for 8 weeks"},{"id":"FG002","title":"Medication Citalopram (40mg Dose)","description":"Citalopram (40mg dose) 40mg daily for 8 weeks"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"17"},{"groupId":"FG002","numSubjects":"22"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"6"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"16"}]}],"dropWithdraws":[{"type":"Excluded from analysis by MRI","reasons":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"14"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Medication Citalopram 20mg","description":"Citalopram (20mg dose)\n\nCitalopram: 20 mg daily for 8 weeks"},{"id":"BG001","title":"Placebo","description":"Placebo: Placebo daily for 8 weeks"},{"id":"BG002","title":"Medication Citalopram 40mg","description":"Citalopram (40mg dose) 40mg daily for 8 weeks"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"54"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"54"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"9"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"45"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"African American","categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"43"}]}]},{"title":"Caucasian","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"6"}]}]},{"title":"Hispanic","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"5"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"54"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Cocaine Use/Treatment Effectiveness Score (TES)","description":"Number of benzoylecgonine negative urines divided by the total number of urines collected","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage of negative urines","timeFrame":"8 weeks of treatment","groups":[{"id":"OG000","title":"Medication (Citalopram 20mg)","description":"Citalopram (20mg dose)\n\nCitalopram: 20 mg or 40 mg daily for 8 weeks"},{"id":"OG001","title":"Placebo","description":"Placebo: Placebo daily for 8 weeks"},{"id":"OG002","title":"Medication (Citalopram 40mg)","description":"Citalopram 40mg dose\n\nCitalopram: 20 mg or 40 mg daily for 8 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6"},{"groupId":"OG001","value":"8.3"},{"groupId":"OG002","value":"29"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"fMRI Brain Activation in Right Inferior Frontal Gyrus","description":"Brain activation on fMRI while participants undergo a Go/Nogo task. Percent of significant cluster in Statistical Parametric Mapping (SPM) for contrast of Hard Nogo minus Easy Nogo correlation with treatment effectiveness score.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percent of significant voxels in cluster","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Citalopram (20mg or 40mg)","description":"Participants treated with citalopram, either 20mg or 40mg"},{"id":"OG001","title":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"fMRI Brain Activation in Right Precentral Gyrus","description":"Brain activation on fMRI while participants undergo a Go/Nogo task. Percent of significant cluster in Statistical Parametric Mapping (SPM) for contrast of Hard Nogo minus Easy Nogo correlation with treatment effectiveness score.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percent of significant voxels in cluster","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Citalopram (20mg or 40mg)","description":"Participants treated with citalopram, either 20mg or 40mg"},{"id":"OG001","title":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"fMRI Brain Activation in Right Orlandic Operculum","description":"Brain activation on fMRI while participants undergo a Go/Nogo task. Percent of significant cluster in Statistical Parametric Mapping (SPM) for contrast of Hard Nogo minus Easy Nogo correlation with treatment effectiveness score.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percent of significant voxels in cluster","timeFrame":"Baseline","groups":[{"id":"OG000","title":"Citalopram (20mg or 40mg)","description":"Participants treated with citalopram, either 20mg or 40mg"},{"id":"OG001","title":"Placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"12 weeks","eventGroups":[{"id":"EG000","title":"Medication (Citalopram 20mg)","description":"Citalopram (20mg dose)\n\nCitalopram: 20 mg or 40 mg daily for 8 weeks","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":0,"otherNumAtRisk":6},{"id":"EG001","title":"Placebo","description":"Placebo: Placebo daily for 8 weeks","deathsNumAffected":0,"deathsNumAtRisk":5,"seriousNumAffected":0,"seriousNumAtRisk":5,"otherNumAffected":0,"otherNumAtRisk":5},{"id":"EG002","title":"Medication (Citalopram 40mg)","description":"Citalopram 40mg dose\n\nCitalopram: 20 mg or 40 mg daily for 8 weeks","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":0,"otherNumAtRisk":6}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Results should be viewed with caution due to small sample size. Data was only analyzed from participants who underwent MRI scans at UT Houston as data could not be combined with MRI scans at VCU."},"certainAgreement":{"piSponsorEmployee":true},"pointOfContact":{"title":"F. Gerard Moeller, M.D.","organization":"VCU","email":"frederick.moeller@vcuhealth.org","phone":"804-828-4134"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D019970","term":"Cocaine-Related Disorders"},{"id":"D019966","term":"Substance-Related Disorders"},{"id":"D007175","term":"Impulsive Behavior"}],"ancestors":[{"id":"D064419","term":"Chemically-Induced Disorders"},{"id":"D001523","term":"Mental Disorders"},{"id":"D001519","term":"Behavior"}]},"interventionBrowseModule":{"meshes":[{"id":"D015283","term":"Citalopram"}],"ancestors":[{"id":"D011437","term":"Propylamines"},{"id":"D000588","term":"Amines"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D009570","term":"Nitriles"},{"id":"D001572","term":"Benzofurans"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}